Saris J, Li Yim A Y F, Bootsma S, Lenos K J, Franco Fernandez R, Khan H N, Verhoeff J, Poel D, Mrzlikar N M, Xiong L, Schijven M P, van Grieken N C T, Kranenburg O, Wildenberg M E, Logiantara A, Jongerius C, Garcia Vallejo J J, Gisbertz S S, Derks S, Tuynman J B, D'Haens G R A M, Vermeulen L, Grootjans J
Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands.
Nat Commun. 2025 Apr 17;16(1):3669. doi: 10.1038/s41467-025-58999-6.
Patients with peritoneal metastasized colorectal cancer (PM-CRC) have a dismal prognosis. We hypothesized that an immunosuppressive environment in the peritoneal cavity underlies poor prognosis. We define the composition of the human peritoneal immune system (PerIS) using single-cell technologies in 18 patients with- and without PM-CRC, as well as in matched peritoneal metastases (n = 8). Here we show that the PerIS contains abundant immunosuppressive C1QVSIG4 and SPP1VSIG4 peritoneal-resident macrophages (PRMs), as well as monocyte-like cavity macrophages (mono-CMs), which share features with tumor-associated macrophages, even in homeostasis. In PM-CRC, expression of immunosuppressive cytokines IL10 and VEGF increases, while simultaneously expression of antigen-presenting molecules decreases in PRMs. These intratumoral suppressive PRMs originate from the PerIS, and intraperitoneal depletion of PRMs in vivo using anti-CSF1R combined with anti-PD1 significantly reduces tumor burden and improves survival. Thus, PRMs define a metastatic site-specific immunosuppressive niche, and targeting PRMs is a promising treatment strategy for PM-CRC.
腹膜转移结直肠癌(PM-CRC)患者预后不佳。我们推测,腹腔内的免疫抑制环境是预后不良的基础。我们使用单细胞技术,对18例有和没有PM-CRC的患者以及匹配的腹膜转移瘤(n = 8)进行研究,以确定人类腹膜免疫系统(PerIS)的组成。我们发现,即使在稳态下,PerIS也含有大量免疫抑制性C1QVSIG4和SPP1VSIG4腹膜驻留巨噬细胞(PRM)以及单核细胞样腹腔巨噬细胞(单核-CM),它们与肿瘤相关巨噬细胞具有共同特征。在PM-CRC中,免疫抑制细胞因子IL10和VEGF的表达增加,而PRM中抗原呈递分子的表达同时减少。这些肿瘤内抑制性PRM起源于PerIS,在体内使用抗CSF1R联合抗PD1对PRM进行腹腔内清除可显著减轻肿瘤负担并改善生存。因此,PRM定义了一个转移部位特异性免疫抑制微环境,靶向PRM是PM-CRC的一种有前景的治疗策略。